Compare Novartis AG (NVS) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Under Armour Inc Class A — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Under Armour Inc Class A trades at $4.88 (market cap $2.07B). The key difference: Novartis AG is far larger — about 129.7× Under Armour Inc Class A's market cap, and Novartis AG pays a 3.31% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Under Armour Inc Class A for 99 Days on average.
| NVS | UAA | |
|---|---|---|
Market Cap | $268.57B | $2.07B |
Volume | 1,532,573 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $8.14 |
52-Week Low | $121.80 | $4.17 |
Typical Hold Time | 82 Days | 99 Days |
Enterprise Value | $309.89B | $3.05B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Under Armour (UAA) trades at $4.82, down 1.23% amid ongoing revenue challenges despite recent earnings beats. The stock shows a bullish technical signal with mixed oscillators, while fundamentals reveal negative profitability metrics including -9.99% net income margin and -29.82% ROE. Recent news highlights the company's brand transformation efforts and international market resilience as it navigates softer North American demand.
The outlook remains cautious with analyst consensus at $5.79 target (20% upside) but 57% hold ratings. Key risks include persistent revenue declines, negative cash flow trends, and competitive pressures. Investment opportunity exists if margin improvements and international growth can offset domestic weakness, but execution risks remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
